Randomized trial · people
CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In east Asian adults, adding cagrilintide to semaglutide gave 6.5 percentage points more weight loss than semaglutide alone over 68 weeks, with similar rates of side effects.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 331
- Published
- 2026
- Journal
- Lancet Diabetes Endocrinol
What they tested
The team tested whether weekly CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) leads to more weight loss than semaglutide 2.4 mg alone in east Asian adults with overweight or obesity.
How the study was done
A double-blind, randomized, active-controlled phase 3a trial in 331 adults with overweight or obesity, with or without type 2 diabetes, at 21 sites in Japan and 1 in Taiwan. Participants got weekly injections of CagriSema or semaglutide alone, both raised step by step to 2.4 mg, plus lifestyle support for 68 weeks.

Model. Individual results vary.
What they found
At 68 weeks, body weight fell by an estimated 18.4% (SE 0.7) with CagriSema and 11.9% (SE 0.7) with semaglutide alone. CagriSema came out ahead of semaglutide by 6.5 percentage points, a gap that was statistically significant. Side effects were reported by 87% of the CagriSema group and 84% of the semaglutide group, mostly stomach and gut problems (53% vs 51%). 10% stopped CagriSema and 6% stopped semaglutide, and one death in the semaglutide group was judged by the investigator as not linked to treatment.
What it doesn’t show
Nearly all sites were in Japan, so the result speaks mainly to east Asian adults, and the main weight result assumes people took the treatment as intended. There was no placebo arm, and the trial was funded by Novo Nordisk.
The paper
Yamauchi et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2026.
The compounds
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.